Why This Stock Now
Eli Lilly has built one of the most productive obesity drug pipelines in the pharmaceutical industry over the past three years. Its flagship tirzepatide franchise, sold as Mounjaro for diabetes and Zepbound for obesity, became the world’s top-selling medicine by 2026 based on quarterly sales comparisons reported in 2026. Then, on May 21, Lilly reported that retatrutide, its next-generation triple agonist, delivered 28.3% average weight loss over 80 weeks in TRIUMPH-1, the largest figure ever reported from a Phase 3 obesity trial. The company has said the full clinical data package is complete and it plans an FDA filing in Q1 2027. Lilly’s Q3 earnings call is scheduled for October 29.
The Business
Lilly’s commercial foundation rests on tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity, and orforglipron, the once-daily pill branded Foundayo that received FDA approval on April 1, 2026. Medicare began covering certain GLP-1 drugs for obesity for the first time this year through a program that started July 1, 2026, expanding access for eligible beneficiaries. Foundayo produced about 11% average weight loss in its pivotal obesity studies, lower than Zepbound but potentially more scalable globally given its small-molecule format and the fact it can be taken any time of day without food or water restrictions. CEO David Ricks has repeatedly emphasized that supply is the limiting factor, and that Lilly intends to manufacture at a scale measured in hundreds of millions of patients.
Lilly has reported 60.1% share of the U.S. incretin market in Q1 2026. Novo Nordisk’s experimental CagriSema fell short versus tirzepatide on glycemic control in a head-to-head Type 2 diabetes comparison reported in August. The competitive lead is widening, not narrowing.
Why Wall Street Is Paying Attention
Second-quarter revenue jumped 48% to $23.0 billion, well ahead of consensus estimates that were around $20.8 billion heading into the quarter. In its August 5 release, Lilly raised its full-year 2026 revenue guidance to $85 to $87 billion. For Q3, published analyst estimates cluster around roughly $22.4 billion in revenue and EPS around $9.9. Cantor Fitzgerald raised its price target to $1,440 on October 8, and the options market has been pricing a mid-single-digit to high-single-digit move around earnings.
What’s Driving the Opportunity
Retatrutide is the central thesis. At the 12mg dose in TRIUMPH-1, participants lost an average of 70.3 pounds over 80 weeks. About 65.3% dropped below the clinical obesity threshold (BMI under 30). Lilly is studying retatrutide across multiple Phase 3 programs, including obesity and obesity-related conditions such as obstructive sleep apnea and knee osteoarthritis. Lilly plans to file for regulatory approval in Q1 2027. TD Cowen estimated retatrutide could reach $3.8 billion in sales by 2030, before accounting for additional indications. That figure was published before the full TRIUMPH-1 data readout and may prove conservative.
What Could Go Wrong
The stock trades at a premium multiple, a valuation that demands consistent outperformance with little room for quarterly misses. Q3 revenue is expected to come in below Q2’s $23.0 billion, partly because the first half benefited from one-time items that will not repeat. Pricing pressure tied to the administration’s most-favored-nation GLP-1 pricing agreement continues to weigh on realized prices for Mounjaro and Zepbound. Retatrutide’s tolerability worsened at higher doses, with discontinuation rates rising as doses climbed. Regulatory timelines can slip, and retatrutide has not been approved anywhere yet.
The Bottom Line
Lilly enters October 29 with a drug that set weight-loss records, a pill that can scale globally, and a regulatory filing for its next compound planned for early 2027. Shares are below their recent highs. The pipeline is among the strongest in pharma. The valuation is elevated. And retatrutide, the most potent weight-loss compound yet reported in a Phase 3 obesity trial, has not been fully priced in by the market.
